High frequency of NAT2 slow acetylator alleles in the Malay population of Indonesia: an awareness to the anti-tuberculosis drug induced liver injury and cancer
Background: Arylamine N-acetyltransferase 2 (NAT2) polymorphism was previously reported to have association with the risk of drug toxicities and the development of various diseases. Previous research on the Indonesian population, especially Javanese and Sundanese, showed that there were 33% NAT2 slow acetylator phenotype. The aim of this study was to map the NAT2 variation in the Malay ethnic to gain a deeper insight into NAT2 haplotypic composition in this ethnic.
Methods: 50 healthy samples from the Indonesian Malay ethnic were obtained. They were interviewed about their ethnic backgrounds for the last three generations. DNA was extracted from peripheral blood and NAT2 genotyping was done using the PCR direct Sequencing. Data were compiled according to the genotype and allele frequencies estimated from the observed numbers of each specific allele. Haplotype reconstruction was performed using PHASE v2.1.1 software.
Results: We found 7 haplotypes consisting of 6 SNPs and 14 NAT2 genotype variations in Indonesian Malay population. The most frequent allele was NAT2*6A (38%) which was classified as a slow acetylator allele. According to bimodal distribution, the predicted phenotype of the Malay population was composed of 62% rapid acetylator and 38% slow acetylator. According to trimodal distribution, the predicted phenotypes for rapid, intermediate and slow acetylators were 10%, 52% and 38% respectively.
Conclusion: Our result indicates the presence of the allelic distribution and revealed the most frequent acetylator status and phenotype for the Indonesian Malay population. The result of this study will be helpful for future epidemiological or clinical studies and for understanding the genetic basis of acetylation polymorphism in Indonesia.
Yuliwulandari R, Sachrowardi Q, Nishida N, Takasu M, Batubara L, Susmiarsih TP, et al. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J Hum Genet. 2008;53(3):201â€“9. https://doi.org/10.1007/s10038-007-0237-z
GarcÃa-MartÃn E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab. 2008;9(6):487â€“97. https://doi.org/10.2174/138920008784892155
McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 2014;24(8):409â€“25. https://doi.org/10.1097/fpc.0000000000000062
Fernandes MR, de Carvalho DC, dos Santos Ã‚K, dos Santos SE, de AssumpÃ§Ã£o PP, Burbano RM, et al. Association of slow acetylation profile of NAT2 with breast and gastric cancer risk in Brazil. Anticancer Res. 2013;33(9):3683â€“9.
Yuliwulandari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016;61(6):533â€“7. https://doi.org/10.1038/jhg.2016.10
Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One. 2011;6(4):e18507. https://doi.org/10.1371/journal.pone.0018507
Ananta A, Arifin E, Hasbullah MS, Handayani NB, Pramono A. Changing ethnic composition in Indonesia, 2000-2010. XXVII IUSSP International Population Conference. 2013:1â€“32. Available from: https://iussp.org/sites/default/files/event_call_for_papers/IUSSP%20Ethnicity%20Indonesia%20Poster%20Section%20G%202708%202013%20revised.pdf
Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978â€“89. https://doi.org/10.1086/319501
Sabbagh A, Darlu P. Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genet. 2005;6:30. https://doi.org/10.1186/1471-2164-6-30
Sabbagh A, Langaney A, Darlu P, GÃ©rard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: Implications for NAT2 evolutionary history. BMC Genet. 2008;9:21. https://doi.org/10.1186/1471-2156-9-21
Selinski S, Blaszkewicz M, Ickstadt K, Hengstler JG, Golka K. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch Toxicol. 2013;87(12):2129â€“39. https://doi.org/10.1007/s00204-013-1157-7
Du H, Chen X, Fang Y, Yan O, Xu H, Li L, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep. 2013;40(5):3591â€“6. https://doi.org/10.1007/s11033-012-2433-y
Gong C, Hu X, Gao Y, Cao Y, Gao F, Mo Z. A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review. Med Oncol. 2011;28(1):365â€“76. https://doi.org/10.1007/s12032-010-9423-5
Unal M, Tamer L, DoÄŸruer ZN, Yildirim H, VayisoÄŸlu Y, Camdeviren H. N-acetyltransferase 2 gene polymorphism and presbycusis. Laryngoscope. 2005;115(12):2238â€“41. https://doi.org/10.1097/01.mlg.0000183694.10583.12
Van Eyken E, Van Camp G, Fransen E, Topsakal V, Hendrickx JJ, Demeester K, et al. Contribution of the N-acetyltransferase 2 polymorphism NAT2*6A to age-related hearing impairment. J Med Genet. 2007;44(9):570â€“8. https://doi.org/10.1136/jmg.2007.049205
Bared A, Ouyang X, Angeli S, Du LL, Hoang K, Yan D, et al. Antioxidant enzymes, presbycusis, and ethnic variability. Otolaryngol Head Neck Surg. 2010;143(2):263â€“8. https://doi.org/10.1016/j.otohns.2010.03.024
Kosova B, Ã‡etintaÅŸ VB, Ã‡al AÃ‡, Tetik A, Ã–zel R, Aktan Ã‡, et al. N-acetyltransferase 2 gene polymorphisms and susceptibility to prostate cancerâ€¯: a pilot study in the Turkish population. Turk J Med Sci. 2010;40(4):629â€“36.
Liu HE, Hsiao PY, Lee CC, Lee JA, Chen HY. NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population. Cancer Epidemiol Biomarkers Prev. 2008;17(3):661â€“5. https://doi.org/10.1158/1055-9965.EPI-07-2647
Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, et al. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis. 2011;32(2):182â€“9. https://doi.org/10.1093/carcin/bgq223
Figueroa JD, Han SS, Garcia-Closas M, Baris D, Jacobs EJ, Kogevinas M, et al. Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis. 2014;35(8):1737â€“44. https://doi.org/10.1093/carcin/bgu064
Ruiz JD, MartÃnez C, Anderson K, Gross M, Lang NP, GarcÃa-MartÃn E, et al. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PLoS One. 2012;7(9):e44629. https://doi.org/10.1371/journal.pone.0044629
Selinski S, Blaszkewicz M, Getzmann S, Golka K. N-Acetyltransferase 2: ultra-slow acetylators enter the stage. Arch Toxicol. 2015;89(12):2445â€“7. https://doi.org/10.1007/s00204-015-1650-2
An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;39(6):535â€“43. https://doi.org/10.1111/j.1440-1681.2012.05713.x
Selinski S, Getzmann S, Gajewski PD, Blaszkewicz M, Hengstler JG, Falkenstein M, et al. The ultra-slow NAT2*6A haplotype is associated with reduced higher cognitive functions in an elderly study group. Arch Toxicol. 2015;89(12):2291â€“303. https://doi.org/10.1007/s00204-015-1635-1
Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol. 2014;70(9):1079â€“86. https://doi.org/10.1007/s00228-014-1703-0
Copyright (c) 2017 Retno W. Susilowati, Kinasih Prayuni, Intan Razari, Syukrini Bahri, Rika Yuliwulandari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.